{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:47:40Z","timestamp":1757699260334},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T00:00:00Z","timestamp":1273449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p> <jats:bold>Background:<\/jats:bold> Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease. There is controversy regarding the prevalence of aspirin resistance in patients with coronary artery disease and the effect of dose on resistance. Our primary aims were to determine the degree of platelet responsiveness to aspirin, and to study the influence of dose on platelet inhibition and clinical outcomes after coronary stenting. <jats:bold>Methods and Results:<\/jats:bold> We prospectively studied the effect of aspirin on platelet function in 106 stable outpatients 6 months after successful percutaneous coronary angioplasty. Participants were randomized in a double\u2010blind, double\u2010crossover study (80 or 500 mg per day for 6 months). The platelet response to aspirin was determined by 10 \u03bcmol\/L adenosine\u20105\u2010diphosphate\u2010induced aggregation with light transmission aggregometry. The clinical outcome was determined by single photon emission computed tomography with Tc\u201099m, and major adverse cardiac events were recorded (myocardial infarction, death, unstable angina or need for revascularization). In both groups 30.2% of the participants were resistant to aspirin. There was no significant difference between the dose of 80\u2003mg compared to 500 mg aspirin in the incidence of aspirin resistance (<jats:italic>P<\/jats:italic>= 0.3). No correlation was found between aspirin resistance and clinical outcome (<jats:italic>P<\/jats:italic>= 0.4). Female sex and smoking were strongly associated with aspirin resistance. <jats:bold>Conclusion:<\/jats:bold> The frequency of aspirin resistance is not dependent on the dose of aspirin. Female sex and smoking were the strongest predictors of aspirin resistance. Aspirin resistance is not a predictor of poor clinical outcome in patients who received double antiplatelet therapy.<\/jats:p>","DOI":"10.1111\/j.1755-5922.2010.00170.x","type":"journal-article","created":{"date-parts":[[2010,5,10]],"date-time":"2010-05-10T08:28:11Z","timestamp":1273480091000},"page":"147-152","source":"Crossref","is-referenced-by-count":12,"title":["Dose\u2010Related Effect of Aspirin on Laboratory\u2010Defined Platelet Aggregation and Clinical Outcome After Coronary Stenting"],"prefix":"10.1111","volume":"28","author":[{"given":"Javad","family":"Kojuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadollah","family":"Mahmoody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bardia Zangbar","family":"Sabegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor","family":"Jannati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mahboodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andia","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,10]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.15.1593"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.10.1206"},{"key":"e_1_2_8_4_2","first-page":"38","article-title":"Experiences with aspirin (acetylsalicylic acid) in the non\u2010specific prophylaxis of coronary thrombosis","volume":"75","author":"Craven L","year":"1953","journal-title":"Miss Val Med J"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.070"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.234S"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy. I. prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6922.159"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6923.235"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.39S"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90164-J"},{"key":"e_1_2_8_14_2","first-page":"1385","article-title":"Results of the BRAT study\u2014a pilot study investigation the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients under going coronary artery bypass surgery","volume":"16","author":"Buchanan MR","year":"2000","journal-title":"Can J Cardiol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00405-X"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013777.21160.07"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)03014-0"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.07.011"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-8952-4"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.01.006"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.10.021"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2007.04.010"},{"key":"e_1_2_8_23_2","first-page":"1186","volume-title":"Drug facts and comparison","author":"Riley MR","year":"2008"},{"key":"e_1_2_8_24_2","first-page":"236","volume-title":"The aspirin wars: Money, medicine and 100 years of Rampant competition","author":"Mann CC","year":"1991"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.207.59"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.12.2331"},{"key":"e_1_2_8_27_2","first-page":"801","article-title":"Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy","volume":"118","author":"Pappas JM","year":"1994","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01631-9"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.08.072"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.12.2027"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000151362.65339.f9"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.2217\/14796678.2.3.343"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-005-0044-0"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000148175.60718.69"},{"key":"e_1_2_8_35_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1590\/S0102-76382007000100017","article-title":"Aspirin resistance and atherothrombosis","volume":"22","author":"Gabriel SA","journal-title":"Braz J Cardiovasc Surg 2007"},{"key":"e_1_2_8_36_2","article-title":"Aspirin responsiveness measured by COX\u20101 specific and COX\u20101 non\u2010specific methods in healthy subjects: Clarifying the debate on aspirin \u2018resistance\u2019","volume":"5","author":"Antonino MJ","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5922.2010.00170.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5922.2010.00170.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:45:09Z","timestamp":1698738309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5922.2010.00170.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1755-5922.2010.00170.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00170.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,10]]}}}